MLLCF News and Press, Molecular Partners AG From 02/10/23

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer...

Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells Preclinical data demonstrated that MP0533 can selectively target and kill both leukemic blast cells and stem cells, while sparing healthy ce...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin ther...

Molecular Partners AG (MOLN) Q2 2022 Earnings Conference Call August 25, 2022, 08:00 AM ET Company Participants Seth Lewis - SVP of IR Patrick Amstutz - CEO Andreas Emmenegger - CFO Conference Call Participants Georgi Yordanov - Cowen and Company ...

The following slide deck was published by Molecular Partners AG in conjunction with their 2022 Q2 earnings call. For further details see: Molecular Partners AG 2022 Q2 - Results - Earnings Call Presentation

Molecular Partners AG (MOLN) Q4 2021 Earnings Conference Call March 16, 2022 08:00 ET Company Participants Seth Lewis - Head, Investor Relations Patrick Amstutz - Chief Executive Officer Andreas Emmenegger - Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Georgi...

The following slide deck was published by Molecular Partners AG in conjunction with this event. For further details see: Molecular Partners (MOLN) Presents at the Credit Suisse Healthcare Conference - Slideshow

Molecular Partners (NASDAQ:MOLN) has issued a statement regarding the recently identified SARS-CoV-2 variant, termed Omicron (B.1.1.529). Ensovibep has been consistently tested in vitro against all existing and potential variants of concerns, and its retains activity with regard to all r...

The first patient has been dosed in Molecular Partners' (MLLCF) new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of Health's ((NIH)) partnership designed to speed development of treatments and vaccine candidates for COVID-19.Also, the FDA has granted ensovibep Fa...

Novartis (NVS) and Molecular Partners (MLLCF) have started the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of novel DARPin therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19.The EMPATHY trial is investigating the safety and efficacy of ensovibep in ea...